The role of non-alcoholic fatty liver disease in the development of cardiovascular diseases


Cite item

Full Text

Abstract

The review describes the pathogenetic mechanisms of the relationship between cardiovascular disease and non-alcoholic fatty liver disease (NAFLD), which is the rationale for selecting therapeutic targets for intervention. The role of insulin resistance, oxidative stress, inflammation, dyslipidemia, intestinal microflora, heredity in the pathological relationship between NAFLD and cardiometabolic disorders are discussed. Present-day data of domestic and foreign scientists on prevalence, etiology, pathogenesis, clinical picture and treatment of this comorbid state are presented. Information is given on the development of subclinical and clinical atherosclerosis, as well as the concept of the hepatocardial continuum. In the treatment of NAFLD, the main role is given to the elimination or correction of etiopathogenetic factors of the development of the disease, excessive body weight, obesity, insulin resistance, hyperglycemia, hyperlipidemia. Particular attention is paid to the issues of dietetic complex intervention and the influence of various nutrition components on the state of the cardiovascular system and the liver.

About the authors

R. A Eganyan

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: eganyan@km.ru
канд. мед. наук, вед. науч. сотр. отд. первичной профилактики ХНИЗ в системе здравоохранения 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Xin X, Linlin L, Quanyong D et al. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis 2015; 14: 158. doi: 10.1186/s12944-015-0141-z
  2. Пальгова Л.К. Группы риска по развитию неалкогольной жировой болезни печени: кому и как проводить скрининг. Эффективная фармакотерапия. 2017; 16: 26-30.]
  3. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. 2016.
  4. Gaggini M, Morelli M, Buzzigoli E et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseases. Nutrients 2013; 5 (5): 1544-60.
  5. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C - natural history and cofactors. Aliment Pharmacol Ther 2005; 22 (Suppl.): 74-8.
  6. Koliaki C, Szendroedi J, Kaul K et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015; 21 (5): 739-46.
  7. Hector J, Schwarzloh B, Goehring J et al. TNF-a Alters Visfatin and Adiponectin Levels in Human Fat. Horm Metab Res 2007; 39: 250-5.
  8. Alkhouri N, Tamimi T.A, Yerian L et al. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci 2010; 55: 2644-50.
  9. Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 193-9. doi: 10.1097/MEG.000000000 0000254
  10. Lim S, Oh T.J, Koh K.K. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. J Cardiol 2015; 201: 408-14. doi: 10.1016/j.ijcard.2015.08.107
  11. Драпкина О.М., Корнеева О.Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2016; 12 (4): 424-9. DOI: http://dx.doi.org/ 10.20996/]
  12. Диагностика и лечение неалкогольной жировой болезни печени. Под ред. В.Т.Ивашкина. М.: РОПИП, 2015
  13. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64 (6): 1388-402.
  14. Younossi Z.M, Koenig A.B, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (1): 73-84.
  15. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31-41.
  16. Ivashkin V.T, Drapkina O.M. The prevalence of nonalcoholic fatty liver disease in Russian Federation. GUT 2009; 58: 1207.
  17. Fraser I.S, Critchley H.O, Munro M.G et al. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol 2009; 4 (2): 179-89.
  18. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 2: 24-42.
  19. Patil R, Sood G.K. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017; 8 (2): 51-8. doi: 10.4291/wjgp.v8.i2.51
  20. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-40.
  21. Fargion S, Porzio M, Fracanzani A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol 2014; 20 (37): 13306-324. doi: 10.3748/wjg.v20.i37.13306
  22. Mellinger J.L, Pencina K.M, Massaro J.M et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol 2015; 63 (2): 470-6. doi: 10.1016/j.jhep.2015.02.045
  23. Bhatia L.S, Curzen N.P, Calder P.C, Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33 (10): 1190-200.
  24. Pacifico L, Chiesa C, Anania C. et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014; 20 (27): 9055-907.
  25. Малявская С.И., Лебедев А.В. Метаболический портрет детей с ожирением. Рос. вестн. перинатологии и педиатрии. 2011; 60 (6): 73-8.
  26. Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54 (1): 145-52.
  27. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2 (6): 335-48.
  28. Ройтберг Г.Е., Шархун О.О., Платонова О.Е., Ушакова Т.И. Неалкогольная жировая болезнь печени как фактор риска атеросклероза. Вестн. РГМУ. 2008; 6: 5-10.
  29. Платонова О.Е. Риск развития атеросклероза у пациентов с неалкогольной жировой болезнью печени при инсулинорезистентности. Автореф. дис.. канд. мед. наук. М., 2009.
  30. Basar O, Akbal E, Köklü S et al. Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis. Herz 2013; 38 (4): 417-22. doi: 10.1007/s00059-012-3714-x
  31. Pais R, Giral P, Khan J.F et al. LIDO Study group, Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 2016; 65 (1): 95-102. doi: 10.1016/j.jhep.2016.02.023
  32. Kim H.C, Kim D.J, Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204 (2): 521-5.
  33. Chalasani N, Younossi Z, Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6): 2005-23. doi: 10.1002/hep.25762
  34. Дауреханов А.М., Шонбаева А.К., Сагиндыков Н.Н. Влияние рака, цирроза печени и хронического вирусного гепатита на развитие атеросклероза. Medicine (Almaty). 2017; 2: 24-9.
  35. Кривошеев А.Б., Куимов А.Д., Попов К.В. и др. Гендерные особенности неалкогольной жировой болезни печени в сочетании с метаболическим синдромом. Атеросклероз. 2016; 2: 25-30.
  36. Драпкина О.М. Континуум неалкогольной жировой болезни печени: от стеатоза до сердечно-сосудистого риска. Рацион. фармакотерапия в кардиологии. 2016; 12: 424-9. / Drapkina O.M. Kontinuum nealkogol'noi zhirovoi bolezni pecheni: ot steatoza do serdechno-sosudistogo riska. Ratsion. farmakoterapiia v kardiologii. 2016; 12: 424-9. [in Russian]
  37. Sung K.C, Wild S.H, Kwag H.J, Byrne .CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012; 35: 2359-64.
  38. Ramilli S, Pretolani S, Muscari A et al. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009; 15 (38): 4770-4.
  39. Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 193-9. doi: 10.1097/MEG.000000000 0000254
  40. Li N, Zhang G.W, Zhang J.R et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25 (2): 218-23. doi: 10.1016/j.numecd.2014.10.002
  41. Pugh T.J, Kelly M.A, Gowinsankar S et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med 2014; 16 (8): 601-8. DOI: 10,1038/gim.2013.204
  42. Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-80.
  43. Perseghin G, Lattuada G, De Cobelli F et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47: 51-8.
  44. Hallsworth K, Hollingsworth K.G, Thoma C et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 2013; 58: 757-62.
  45. Bonapace S, Perseghin G, Molon G et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-95.
  46. Targher G, Valbusa F, Bonapace S et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8: e57183.
  47. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 2014; 22: 332-6.
  48. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13 (10): 1579-84.
  49. Wong V.W, Wong G.L, Yip G.W et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-7.
  50. Dunn W, Xu R, Wingard D.L et al. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study. Am J Gastroenterol 2008; 103: 2263-71.
  51. Ong J.P, Pitts A, Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
  52. Li J, Ma W, Wang S. Slower gastric emptying in high-fat diet induced obese rats is associated with attenuated plasma ghrelin and elevated plasma leptin and cholecystokinin concentrations. Regul Pept 2011; 171: 53-7.
  53. Bendsen N.T, Chabanova E, Thomsen H.S et al. Effect of trans fatty acid intake on abdominal and liver fat deposition and blood lipids: a randomized trial in overweight postmenopausal women. Nutr Diabetes 2011; 1 (1): e4. doi: 10.1038/nutd.2010.4
  54. Ross A.В, Taylor C.L, Yaktine A et al. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US), 2011.
  55. Лазебник Л.Б., Звенигородская Л.А., Егорова Е.Г. и др. Неалкогольная жировая болезнь печени при дислипидемии и инсулинорезистентности: сходство и различия; дифференцированный подход к терапии. Эксперим. и клин. гастроэнтерология. 2009; 4: 4-11.
  56. Тутельян В.А., Вялков А.И., Разумов А.Н. и др. Научные основы здорового питания. М.: Панорама, 2010.
  57. Кардиоваскулярная профилактика. Национальные клинические рекомендации. М., 2009
  58. Чеснокова Л.В., Петров И.М., Трошина И.А. и др. Влияние снижения массы тела на течение неалкогольной жировой болезни печени: результаты 6-месячного проспективного наблюдения. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 25 (1): 66-73.
  59. Чеснокова Л.В., Петров И.М., Трошина И.А., Медведева И.В. Содержание провоспалительных цитокинов в зависимости от стадии фиброза у больных с метаболическим синдромом и неалкогольной жировой болезнью печени. Клин. медицина. 2013; 12 (91): 34-8

Copyright (c) 2018 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies